3 SEHK Growth Companies With High Insider Ownership

As global markets experience fluctuations and major indices show mixed performance, the Hong Kong market continues to attract attention from investors looking for growth opportunities. In this environment, companies with high insider ownership often stand out as they signal strong confidence from those closest to the business. When considering growth stocks in such a volatile setting, it's crucial to look at firms where insiders have significant stakes. This can indicate alignment of interests between management and shareholders, potentially leading to better long-term performance.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name	Insider Ownership	Earnings Growth
Laopu Gold (SEHK:6181)	36.4%	34.7%
Akeso (SEHK:9926)	20.5%	54.7%
Fenbi (SEHK:2469)	33%	22.4%
Zylox-Tonbridge Medical Technology (SEHK:2190)	18.8%	69.8%
Pacific Textiles Holdings (SEHK:1382)	11.2%	37.7%
Zhejiang Leapmotor Technology (SEHK:9863)	14.7%	78.9%
DPC Dash (SEHK:1405)	38.2%	104.2%
Beijing Airdoc Technology (SEHK:2251)	29.1%	93.4%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	13.9%	109.2%
MicroTech Medical (Hangzhou) (SEHK:2235)	25.8%	105%

Click here to see the full list of 46 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

Meituan (SEHK:3690)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meituan operates as a technology retail company in the People’s Republic of China with a market cap of HK$744.92 billion.

Operations: The company generates revenue from two main segments: Core Local Commerce at CN¥228.13 billion and New Initiatives at CN¥77.56 billion.

Insider Ownership: 11.6%

Meituan, a prominent growth company with high insider ownership in Hong Kong, has shown significant earnings growth of 175.5% over the past year and is expected to continue growing at 25.8% annually over the next three years, outpacing the Hong Kong market's forecasted growth rate. Despite trading at 67.9% below its estimated fair value, recent buybacks totaling HKD 7.17 billion underscore strong internal confidence in its future prospects amidst robust revenue increases and substantial net income improvements for H1 2024.

• Unlock comprehensive insights into our analysis of Meituan stock in this growth report.
• In light of our recent valuation report, it seems possible that Meituan is trading behind its estimated value.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc., a biopharmaceutical company with a market cap of HK$53.38 billion, focuses on researching, developing, manufacturing, and commercializing antibody drugs.

Operations: Revenue from the research, development, production, and sale of biopharmaceutical products amounts to CN¥1.87 billion.

Insider Ownership: 20.5%

Akeso, a growth-focused company in Hong Kong with high insider ownership, is expected to achieve profitability within three years and has a robust revenue growth forecast of 33.1% annually, significantly above the market average. Despite trading at 53.5% below its estimated fair value and experiencing shareholder dilution over the past year, recent advancements in its PD-1/VEGF bispecific antibody drug ivonescimab highlight strong clinical potential and strategic positioning in the oncology sector.

• Navigate through the intricacies of Akeso with our comprehensive analyst estimates report here.
• In light of our recent valuation report, it seems possible that Akeso is trading beyond its estimated value.

RemeGen (SEHK:9995)

Simply Wall St Growth Rating: ★★★★★☆

Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of HK$12.31 billion.

Operations: The company generates revenue primarily from the discovery, development, and commercialization of biologics targeting autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

Insider Ownership: 16.1%

RemeGen, a Hong Kong growth company with high insider ownership, is forecast to achieve 26.3% annual revenue growth and become profitable within three years. Despite recent volatility and a net loss of CNY 780.46 million for H1 2024, the company’s innovative drug telitacicept shows promise with significant regulatory milestones in the U.S. and China. Trading at 88.3% below its estimated fair value, RemeGen's strong clinical developments underscore its potential in treating autoimmune diseases.

• Click here to discover the nuances of RemeGen with our detailed analytical future growth report.
• Our valuation report unveils the possibility RemeGen's shares may be trading at a discount.

Taking Advantage

• Dive into all 46 of the Fast Growing SEHK Companies With High Insider Ownership we have identified here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com